替吉奥或卡培他滨联合奥沙利铂治疗晚期胃癌的疗效观察Δ

Abstract

目的：观察替吉奥或卡培他滨联合奥沙利铂治疗晚期胃癌的有效性与安全性。方法：选取2009年9月—2012年9月就诊的晚期胃癌患者90例，以随机数字表法分为2组各45例，2组患者均给予奥沙利铂130 mg／m2、第1、8日。在此基础上，治疗组患者给予卡培他滨2000 mg／m2，分2次口服，第1—14日；对照组患者给予替吉奥胶囊60 mg／m2，分2次口服，第1—14日。21 d为1个周期，至少化疗3个周期，总疗程不超过6个月。结果：治疗组患者的客观缓解率、疾病控制率、中位生存期及中位生存期分别为48．88％（22／45）、75．55％（34／45）、12．10及4．96个月，对照组分别为51．11％（23／45）、73．33％（33／45）、11．21及5．32个月，2组的差异均无统计学意义（ P＞0．05）；2组患者发生的Ⅲ、Ⅳ级药品不良反应主要为血液学毒性、消化道反应和手足综合征等。结论：替吉奥或卡培他滨联合奥沙利铂化疗都是治疗晚期胃癌的有效方法，均具有较高的缓解率，并能改善患者的无进展生存期及总生存期，安全性较好。

OBJECTIVE:To observe the efficacy and safety of Tegafur gimeracil oteracil potassium capsules combined with oxaliplatin in treatment of advanced gastric cancer.METHODS:90 patients with advanced gastric cancer admitted from Sept.2009 to Sept.2009 were selected to be divided into two groups via the random number table, with 45 cases in each. Two groups were given oxaliplatin 130 mg/m2 in the 1st and 8th day; and based on which the observation group were additionally treated with oral capecitabine 2 000 mg/m2 for twice in the 1st to 14th day;while the control group received Tegafur gimeracil oteracil potassium capsules 60 mg/m2 for twice in the 1st to 14th day.21d as a cycle, 3 cycles was applied at least, the total course was 6 months at most.RESULTS: The objective response rate, disease control rate, median overall survival time and progression-free survival time in observation group were respectively 48.88%(22/45), 75.55%(34/45), 12.10 months and 4.96 months, and in control group were respectively 51.11%(23/45), 73.33%(33/45), 11.21 months and 5.32 months, the difference was not statistically significant(P>0.05).The occurrence ofⅢ,Ⅳgrade adverse drug reactions in two groups were mainly hematological toxicity, gastrointestinal disorder and diarrhea and hand-foot syndrome, etc..CONCLUSIONS: Both tegafur gimeracil oteracil potassium capsules and capecitabine combined with oxaliplatin in treatment advanced gastric cancer were effective, which have high remission rate and can improve the progression-free survival time and overall survival time with high safety.